Drug Type Monoclonal antibody |
Synonyms FG-M108, M 108 |
Target |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors) |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
CLDN18.2 positive Gastroesophageal junction adenocarcinoma | Phase 3 | CN | 04 Dec 2023 | |
CLDN18.2 positive stomach adenocarcinoma | Phase 3 | CN | 04 Dec 2023 | |
Gastrointestinal Neoplasms | Phase 2 | - | - | |
Pancreatic Cancer | Phase 2 | - | - | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 11 Jun 2021 | |
Bile Duct Neoplasms | Phase 1 | - | - | |
Pancreatic carcinoma non-resectable | IND Approval | CN | 19 Apr 2024 |